Tumor necrosis factor inhibitor drug helps to stop physiologic response to tumor necrosis factor.
This report contains market size and forecasts of Tumor Necrosis Factor Inhibitor Drug in global, including the following market information:
Global Tumor Necrosis Factor Inhibitor Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Tumor Necrosis Factor Inhibitor Drug Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Tumor Necrosis Factor Inhibitor Drug companies in 2021 (%)
The global Tumor Necrosis Factor Inhibitor Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Humira Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Tumor Necrosis Factor Inhibitor Drug include AbbVie Inc., Amgen Inc., Johnson & Johnson, UCB, Novartis AG, Pfizer, Inc., Merck & Co., Inc., CASI Pharmaceuticals and EPIRUS Biopharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Tumor Necrosis Factor Inhibitor Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Tumor Necrosis Factor Inhibitor Drug Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Tumor Necrosis Factor Inhibitor Drug Market Segment Percentages, by Type, 2021 (%)
Humira
Enbrel
Remicade
Simponi
Cimzia
Biosimilars
Global Tumor Necrosis Factor Inhibitor Drug Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Tumor Necrosis Factor Inhibitor Drug Market Segment Percentages, by Application, 2021 (%)
Rheumatoid Arthritis
Psoriatic Arthritis
Juvenile Idiopathic Arthritis
Crohn’s Disease
Ulcerative Colitis
Others
Global Tumor Necrosis Factor Inhibitor Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Tumor Necrosis Factor Inhibitor Drug Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Tumor Necrosis Factor Inhibitor Drug revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Tumor Necrosis Factor Inhibitor Drug revenues share in global market, 2021 (%)
Key companies Tumor Necrosis Factor Inhibitor Drug sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Tumor Necrosis Factor Inhibitor Drug sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AbbVie Inc.
Amgen Inc.
Johnson & Johnson
UCB
Novartis AG
Pfizer, Inc.
Merck & Co., Inc.
CASI Pharmaceuticals
EPIRUS Biopharmaceuticals
LEO Pharma
PROBIOMED
Shanghai Pharmaceuticals Holding Co., Ltd.